IFLR1000

Cheplapharm Arzneimittel €780 million refinancing

16/7/2018
Refinancing
Select tab

€ 780 million

$ 912 million

Announced

16/7/2018

Overview:

  • The refinancing consists of a €530 million seven years term loan and a €250 million six years revolving credit facility.
  • Deutsche Bank, HSBC and Unicredit acted as bookrunners.
  • Cheplapharm Arzneimittel is a German manufacturer of pharmaceutical products.

Mihail Georgiev - Data analyst

 

Jurisdiction:

Germany

Deal type:

Refinancing

Practice area:

Banking and finance

Governing law:

Germany

Industry sector:

Pharmaceuticals and life sciences

Firm:
Latham & Watkins

Party: Cheplapharm Arzneimittel GmbH (Borrower)

Lawyers: Alexandra Hagelüken, Cora Grannemann, Martina Eisgruber

Related deals